Losartan Potassium
Product Images NDC 71610-260

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 71610-260). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 25 mg (71610 0260 30)

Losartan Potassium USP 25mg tablet bottle label from Aphena Pharma Solutions - Tennessee, LLC. The label shows a 30 count container with storage instructions, manufacturer information (Torrent Pharmaceuticals Ltd., Mehsana, India), and NDC 71610-0260-30. It is marked Rx only and includes lot number and expiration date details.*

FDA Label Image

Figure 1 (92296151 E507 41b4 A040 C01b87ecb982 01)

Chemical structure of losartan potassium displayed as a molecular diagram showing rings, bonds, and atoms including chlorine, nitrogen, potassium ion, and hydroxyethyl side chains.*

FDA Label Image

Figure 2 (92296151 E507 41b4 A040 C01b87ecb982 02)

A line graph comparing the percentage of patients reaching the primary endpoint over up to 66 months between Atenolol and Losartan Potassium Tablets. The x-axis shows study months, and the y-axis shows percentage of patients. The graph notes an adjusted risk reduction of 13% for Losartan Potassium Tablets with a p-value of 0.021.*

FDA Label Image

Figure 3 (92296151 E507 41b4 A040 C01b87ecb982 03)

A line chart comparing the percentage of patients with fatal or non-fatal stroke over months of study for Atenolol and Losartan Potassium tablets. The chart shows a steadily increasing proportion of events, with Losartan Potassium exhibiting a lower curve indicating fewer events compared to Atenolol. The graph also notes an adjusted risk reduction of 25% with Losartan Potassium with a p-value of 0.001.*

FDA Label Image

Figure 4 (92296151 E507 41b4 A040 C01b87ecb982 04)

A forest plot chart comparing hazard ratios with 95% confidence intervals for Losartan Potassium Tablets versus Atenolol in overall composite outcomes and stroke (fatal/non-fatal) events. The chart breaks down results by patient age, gender, race, presence of ischemic heart disease (ISH), diabetes, and history of cardiovascular disease (CVD). It visually represents event rates and the favorability of each treatment group.*

FDA Label Image

Figure 5 (92296151 E507 41b4 A040 C01b87ecb982 05)

A line graph comparing the percentage of patients with an event over a 48-month period between Losartan Potassium Tablets and placebo groups. The graph shows risk reduction of 16.1% with a p-value of 0.022, with time in months on the x-axis and percentage of patients with event on the y-axis.*

FDA Label Image

Figure 6 (92296151 E507 41b4 A040 C01b87ecb982 06)

FDA Label Image

Figure 6 (92296151 E507 41b4 A040 C01b87ecb982 07)

FDA Label Image

Aphena Pharma Solutions (TN)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.